Nuformix plc (FRA:1RT)

Market Cap	5.68M +272.5%
Revenue (ttm)	n/a
Net Income	-747.64K
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.0010
Previous Close	0.0010
Day's Range	0.0010 - 0.0010
52-Week Range	0.0005 - 0.0190
Beta	n/a
RSI	46.10
Earnings Date	Jan 30, 2026

About Nuformix

Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The company develops NXP001, which is in the Phase 1 stage for use in oncology supportive care; NXP002, which is in the pre-clinical stage for the treatment of idiopathic pulmonary fibrosis; and NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology. It has a licensing agreement with Oxilio Ltd. for NX...

• Industry: Pharmaceutical Preparations
• Founded: 2008
• Employees: 3
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 1RT

Financial Performance

Financial numbers in GBP